Last updated: May 25, 2026
BALVERSA (erdafitinib) is supplied through vertically coordinated branded manufacturing and drug-substance sourcing tied to the branded product’s regulatory listings. The current supplier map is constrained by what is disclosed in FDA product and labeling records, Orange Book maintenance filings, and publicly listed manufacturing site disclosures.
Who supplies BALVERSA (erdafitinib) drug product and drug substance?
Answer: The drug product and drug substance supply chain for BALVERSA is disclosed via FDA labeling manufacturing information and FDA product listings (NDC labeler/manufacturer fields). These records map the responsible manufacturer(s) for the finished dosage form and the listed manufacturer(s) for the active ingredient and/or intermediate steps tied to the NDA.
BALVERSA label-listed manufacturers (finished dosage form)
FDA labeling for BALVERSA specifies the drug product manufacturer responsible for commercial release for the tablets and the package labeling entity shown on the carton. Those entries typically identify:
- Finished-dose manufacturer (site address tied to the NDA labeling)
- Labeler/marketer associated with the NDC record
- Supplier/manufacturing controls at the drug product level (as described in the “Manufactured for” and “Distributed by” sections)
BALVERSA label-listed API manufacturers (drug substance)
FDA product labeling for BALVERSA also identifies the drug substance manufacturer(s) where provided, often via:
- “Manufactured for” language at the API or intermediate level
- Section-level “Manufactured by” or “Distributed by” at the end of the prescribing information
- Nonclinical/chemistry disclosure in labeling supplements (when incorporated)
What this means for sourcing
For procurement and continuity planning, the practical supplier set is the set of sites named in FDA label and NDC records. For IP and licensing, the key constraint is that generic substitution depends on which manufacturing sites and process patents are implicated by Orange Book-listed patents for drug substance, drug product, and formulation/methods.
What is the Orange Book status of BALVERSA, and how does it affect supplier access?
Answer: BALVERSA’s Orange Book status governs when generic and “authorized” supply can enter via ANDA (or potentially via 505(b)(2) routes), based on listed patent expirations and exclusivity. Supplier access is impacted because contract manufacturing and API procurement must clear the Orange Book-linked IP barrier for the product and any covered manufacturing processes.
Orange Book listings that constrain suppliers
For BALVERSA, supplier entry risk centers on:
- Drug substance composition claims
- Drug product formulation claims
- Method of manufacture claims tied to API or final tablet production
- Method-of-use claims (less relevant to supply chain feasibility, more relevant to licensing/launch timing)
Why Orange Book matters operationally
Even if a supplier can make erdafitinib, commercial supply for an FDA-approved generic requires an IP position (carve-out, license, or challenge) aligned with Orange Book-listed patents tied to the NDA.
Which companies can supply BALVERSA tablets under contract manufacturing models?
Answer: Only companies with FDA-recognized manufacturing capability can supply erdafitinib tablets for the NDA’s commercial chain, and they must operate under the manufacturing authorization and quality system controls used in the approved NDA supply.
Contract manufacturing realities
In most kinase inhibitor small molecules, contract manufacturing and packaging are handled by:
- API and intermediate synthesis CDMOs named in regulatory filings or label information
- Tablet formulation and final batch release sites named in the NDA manufacturing section
- Secondary packaging and distribution sites linked to the NDC labeler
The supplier set is therefore not “any API CDMO,” but the specific FDA-linked sites.
What generic entry risks exist for erdafitinib (BALVERSA), and who would be positioned to supply?
Answer: Generic entry risks cluster around Orange Book patent lifetimes and patent dispute outcomes. Any company positioned to supply generics would need:
- An approved ANDA/505(b)(2) route
- A legally cleared formulation and manufacturing strategy
- ANDA bioequivalence readiness and chemistry controls
Paragraph IV and ANDA-linked supply
Where Paragraph IV challenges occur, the supplier set typically shifts to the ANDA filer’s chosen:
- API supplier(s)
- Tablet manufacturer(s)
- Packaging/distribution partners
- NDA-level logistics for commercial launch
Practical supplier shift drivers
Generic manufacturing sourcing usually changes based on:
- Process patent restrictions
- API crystallization/polymorph or impurity control constraints
- Scale-up validation timelines
- Regulatory inspection readiness at the chosen sites
How do supplier and licensing requirements differ for BALVERSA tablets versus other erdafitinib forms?
Answer: BALVERSA is a specific oral tablet strength and dosing regimen. Supplier readiness for generic or parallel supply depends on matching the approved tablet formulation and manufacturing process controls that correspond to label and Orange Book coverage.
Dosage form linkage
Any supplier switch is assessed at:
- Tablet composition targets
- Dissolution profile alignment
- Impurity profile controls
- Stability and packaging controls tied to shelf-life claims
What manufacturing/IP barriers can block new suppliers for BALVERSA?
Answer: The barriers are primarily patent-protected manufacturing steps and formulation-specific IP, plus regulatory compliance at the manufacturing sites.
Common barrier categories
- API manufacturing method claims (process route, purification steps)
- Crystallization/polymorph control claims
- Tablet formulation composition claims (excipients, particle engineering)
- Tablet manufacturing methods (granulation, compression, coating)
- Stability/packaging-related claims (when separately listed)
Timeline: when do BALVERSA suppliers gain market access for generics?
Answer: Supplier access depends on Orange Book patent expirations and any exclusivity. The launch timeline for any new supply is set by:
- Patent expiry dates for the latest-listed relevant claims
- Any statutory/regulatory exclusivities that delay ANDA approval or switch-on
What to use for a launch window
A supply plan should map:
- Latest patent expiration for the applicable NDA
- Any exclusivity periods that block approval
- Any granted stays or settlement-driven launch dates
- Any FDA “suitability” inspections that can delay commercial readiness
Key Takeaways
- BALVERSA supply is anchored to FDA-recognized manufacturing sites shown in labeling and NDC records; those are the actionable supplier starting points for procurement planning.
- Orange Book-listed patents control when new suppliers can commercialize erdafitinib tablets through ANDAs/505(b)(2) routes, even if API synthesis capability exists.
- Supplier entry risk is highest at the points of:
- API process and purification
- tablet formulation and manufacturing methods
- settlement-driven launch timing tied to patent litigation outcomes
FAQs
- What FDA labeling fields identify the BALVERSA tablet manufacturer and labeler for procurement?
- How does Orange Book patent expiry for erdafitinib determine when a generic supplier can ship?
- What types of patents most often block contract manufacturing for small-molecule kinase inhibitors like BALVERSA?
- What manufacturing site inspection factors most delay NDA or ANDA scale-up for oral kinase inhibitors?
- How do settlement agreements in erdafitinib patent cases change the generic supplier launch calendar?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (erdafitinib entry). U.S. Food and Drug Administration.
- FDA. Drug Approval Package and prescribing information for BALVERSA (erdafitinib). U.S. Food and Drug Administration.
- FDA. NDC directory entries for BALVERSA (erdafitinib tablets). U.S. Food and Drug Administration.
